The Recovery Trial: Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

The findings of this well done randomized controlled trial indicate that in patients with COVID-19 pneumonia, that dexamethasone improves 28d mortality compared to placebo in patients requiring invasive mechanical ventilation (IMV) (NNT = 8.5) and those patients requiring oxygen therapy (NNT = 29).  There was no benefit to patients not requiring oxygenation support and even a signal for harm.  It is important to remember this is a preprint, preliminary report, which is better than a press release. At this time, in patients requiring any oxygen therapy, HFNC, NIV, IMV, or ECMO I would recommend dexamethasone until further evidence disproves this benefit.

Emergency Medicine Kenya Foundation

Join Our Newsletter

Please complete this form to create an account, receive email updates and much more.
Contact Email *
First Name *
Last Name *
Facility or Organisation *
Designation or Occupation *
County or City *
Country *
Mobile number 
*
*Required Fields
I agree to the Privacy Policy and Terms of Use. It is our responsibility to protect your privacy and we guarantee that your data will be completely confidential.
Strengthening emergency healthcare systems in Kenya to save lives.